Picture of Hybrigenics SA logo

ALHYG Hybrigenics SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+7.61%
3m-20.75%
6m-57.25%
1yr-83.3%
Volume Change (%)
10d/3m+276.25%
Price vs... (%)
52w High-84.95%
50d MA-4.95%
200d MA-58%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4.65%
Return on Equity-0.96%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Hybrigenics SA EPS forecast chart

Profile Summary

Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.

Directors

Last Annual
December 31st, 2021
Last Interim
December 31st, 2021
Incorporated
January 1st, 1998
Public Since
December 17th, 2007
No. of Employees
17
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
261,249,246

ALHYG Share Price Performance

Upcoming Events for ALHYG

Similar to ALHYG

Picture of AbL Diagnostics SA logo

AbL Diagnostics SA

fr flag iconEuronext - Paris

Picture of Affluent Medical SAS logo

Affluent Medical SAS

fr flag iconEuronext - Paris

Picture of Alpha MOS SA logo

Alpha MOS SA

fr flag iconEuronext - Paris

Picture of Amplitude Surgical SA logo

Amplitude Surgical SA

fr flag iconEuronext - Paris

Picture of Biomerieux SA logo

Biomerieux SA

fr flag iconEuronext - Paris

FAQ